The growing diversity and spectrum of action of myeloid-derived suppressor cells

European Journal of Immunology

Volumn 40, Issue 12, 2010, Pages 3317-3320

  Mantovani, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Macrophages; Myeloid derived suppressor cells; Neutrophils

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CHRONIC INFLAMMATION; HUMAN; MACROPHAGE; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL;

ANIMALS; ANTIGENS, LY; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INTERLEUKIN-1BETA; MICE; MYELOID CELLS; NEOPLASMS; RECEPTORS, CANNABINOID; TUMOR ESCAPE;

EID: 78649604938     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041170     Document Type: Article

References (40)

1. Biswas, S. K. and Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010. 11: 889-896.
2. Gabrilovich, D. I. and Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009. 9: 162-174.
3. Bronte, V., Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur. J. Immunol. 2009. 39: 2670-2672.
4. Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M. and Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007. 179: 977-983.
5. Sica, A. and Bronte, V., Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007. 117: 1155-1166.
6. Hegde, V. L., Nagarkatti, M. and Nagarkatti, P. S., Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol. 2010. 40: 3358-3371.
7. Elkabets, M., Ribeiro, V. S. G., Dinarello, C. A., Ostrand-Rosemberg, S., Di Santo, J. P., Apte, R. N. and Vosshenrich, C. A. J., IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 2010. 40: 3347-3357.
8. Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S. et al., Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010. 32: 790-802.
9. Stewart, T. J., Liewehr, D. J., Steinberg, S. M., Greeneltch, K. M. and Abrams, S. I., Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells. J. Immunol. 2009. 183: 117-128.
10. Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H. and Yu, H., Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008. 118: 3367-3377.
11. Apolloni, E., Bronte, V., Mazzoni, A., Serafini, P., Cabrelle, A., Segal, D. M., Young, H. A. and Zanovello, P., Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 2000. 165: 6723-6730.
12. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S. and Carbone, D. P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998. 92: 4150-4166.
13. Ochoa, A. C., Zea, A. H., Hernandez, C. and Rodriguez, P. C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007. 13: 721s-726s.
14. Sinha, P., Clements, V. K., Fulton, A. M. and Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007. 67: 4507-4513.
15. Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., and Apte, R. N., CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005. 175: 8200-8208.
16. Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J. and Ostrand-Rosenberg, S., Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007. 67: 10019-10026.
17. Marrache, F., Tu, S. P., Bhagat, G., Pendyala, S., Osterreicher, C. H., Gordon, S., Ramanathan, V. et al., Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008. 135: 1277-1287.
18. Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S. et al., Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008. 14: 408-419.
19. Zhang, Y., Liu, Q., Zhang, M., Yu, Y., Liu, X. and Cao, X., Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J. Immunol. 2009. 182: 3801-3808.
20. Mantovani, A., Allavena, P., Sica, A. and Balkwill, F., Cancer-related inflammation. Nature 2008. 454: 436-444.
21. Garlanda, C., Anders, H. J. and Mantovani, A., TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009. 30: 439-446.
22. Dinarello, C. A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009. 27: 519-550.
23. Priceman, S. J., Sung, J. L., Shaposhnik, Z., Burton, J. B., Torres-Collado, A. X., Moughon, D. L., Johnson, M. et al., Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010. 115: 1461-1471.
24. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P. and Van Ginderachter, J. A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008. 111: 4233-4244.
25. Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R. and Ochoa, A. C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009. 69: 1553-1560.
26. Yang, C.-W., Strong, B. S. I., Miller, M. J. and Unanue, E. R., Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J. Immunol. 2010. 185: 2927-2934.
27. Cassatella, M. A., Locati, M. and Mantovani, A., Never underestimate the power of a neutrophil. Immunity 2009. 31: 698-700.
28. Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S. and Alberlda, S. M., Polarization of tumor-associated neutrophil (TAN) phenotype by TGF-beta: "N1" versus "N2" TAN - a new paradigm? Cancer Cell 2009 16: 183-194.
29. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M. et al., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010. 70: 5728-5739.
30. Li, H., Han, Y., Guo, Q., Zhang, M. and Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009. 182: 240-249.
31. Greifenberg, V., Ribechini, E., Rossner, S. and Lutz, M. B., Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009. 39: 2865-2876.
32. Nausch, N., Galani, I. E., Schlecker, E. and Cerwenka, A., Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 2008. 112: 4080-4089.
33. Bellora, F., Castriconi, R., Dondero, A., Reggiardo, G., Moretta, L., Mantovani, A., Moretta, A. and Bottino, C., Human natural killer cells and unpolarized or polarized macrophages: molecular interactions and differences in functional outcome. Proc. Natl. Sci. USA 2010. In press.
34. Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S. and Djeu, J. Y., A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010. 16: 4583-4594.
35. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. and Albelda, S. M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005. 11: 6713-6721.
36. Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H. and Bear, H. D., Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009. 9: 900-909.
37. Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A. et al., Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009. 15: 2148-2157.
38. Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., Rini, B. et al., Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010. 70: 3526-3536.
39. Mantovani, A., Polentarutti, N., Luini, W., Peri, G. and Spreafico, F., Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J. Natl. Cancer Inst. 1979. 63: 61-66.
40. Mantovani, A., From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur. J. Immunol. 2008. 38: 3269-3273.